Cardiol Therapeutics (TSE:CRDL) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Cardiol Therapeutics Inc., a clinical-stage life sciences company, has announced their virtual Annual General and Special Meeting of Shareholders to be webcasted on June 26, 2024. The company, known for its development of anti-inflammatory and anti-fibrotic therapies for heart disease, is advancing clinical studies of its lead drug, CardiolRx™, with FDA approval for trials in pericarditis and myocarditis. Cardiol is also progressing with CRD-38, a new drug formulation aimed at treating heart failure, a major cause of mortality and hospitalization.
For further insights into TSE:CRDL stock, check out TipRanks’ Stock Analysis page.
